• CDK4/6–BET Synergy in Pancreatic Cancer

  2026-10-15

  Gu et al. reported that palbociclib restrained pancreatic ductal adenocarcinoma growth but unexpectedly enhanced migration, invasion, and epithelial-to-mesenchymal transition through a GSK3β–Wnt/β-catenin response linked to TGF-β/Smad signaling. BET inhibition with JQ1 countered these effects and produced stronger antitumor activity in cell and orthotopic mouse models. The findings are mechanistically informative but remain preclinical and do not establish a role for the PI3K inhibitor GDC-0941, which was not identified as a study material.

• What the Product Record Establishes About Mouse IL-7 mRNA

  2026-10-15

  The APExBIO listing identifies EZ Cap™ Mouse IL-7 mRNA (m1Ψ, HA tag), SKU R1054, as a mouse IL-7 mRNA product with a modified-nucleoside designation and an HA-tag designation. No identity-matched research study, outcome data, comparator, or independent validation is available in the supplied materials. Accordingly, the defensible interpretation is limited to product identity, molecular-format implications, measurement boundaries, and the distinction between a named construct and demonstrated biological performance.

• Br-DAPI: What the Product Record Supports

  2026-10-14

  The APExBIO product description presents Br-DAPI as a DAPI fluorescent dye that binds A/T-rich regions in double-stranded DNA and becomes substantially more fluorescent on binding. That mechanism supports a conceptual role in DNA-associated fluorescence measurements, including supplier-described live and fixed cell staining, but no identity-matched study or independent performance data are available here.

• WTAP–GLS Splicing and Ferroptosis in HCC

  2026-10-14

  The supplied study proposes that EGFR–AKT signaling promotes a WTAP-dependent GLS isoform switch that supports glutamine use, antioxidant production, ferroptosis resistance, and hepatocellular carcinoma progression. Its multi-level design strengthens the mechanistic model, but the evidence remains bounded by incomplete reporting, model dependence, and correlational human data. Dehydroabietic acid is a separate supplier-described dual PPAR-α/γ agonist; the study provides no evidence that it affects this WTAP–GLS pathway.

• What the Fabp4 CRISPRi Study Shows—and Does Not

  2026-10-13

  A 2019 mouse study reported that adipocyte-targeted CRISPR interference against Fabp4 was associated with improvements in obesity-related phenotypes. The supplied evidence does not show that Dehydroabietic acid was used in that study or that its supplier-described dual PPAR-α/γ activity reproduces the reported gene-regulation effects. The findings remain preclinical and have important evidentiary and applicability limits.

• Canagliflozin and Renal Mitochondrial Remodeling

  2026-10-13

  A preclinical study in hypertensive–diabetic mice links Canagliflozin exposure with improved proximal-tubule mitochondrial structure and bioenergetics, while emphasizing sex-specific responses and limits on translation beyond the animal model.

• Thapsigargin in Context: Stress-Pathway Evidence

  2026-10-12

  Thapsigargin is a SERCA pump inhibitor commonly used to interrogate calcium signaling and endoplasmic reticulum stress, whereas the supplied 2024 Autophagy study examined metabolic and lysosomal stress through an AMPK–SQSTM1/p62–NRF2 feedback system. The study offers mechanistic insight but does not establish that thapsigargin reproduces this pathway or that findings from cellular and cancer models translate directly to clinical disease.

• VX-765 in Context: IL-1β Processing Study

  2026-10-12

  A source-grounded overview of a bioRxiv preprint examining how inflammatory caspases recognize and process IL-1β and IL-18, with clarification of what the findings do—and do not—establish about VX-765 and VRT-043198.

• CHIR 99021 Trihydrochloride: Evidence and Limits

  2026-10-10

  A source-grounded overview of CHIR 99021 trihydrochloride as a GSK-3 inhibitor, explaining its mechanistic rationale, the relevance of human intestinal organoid research, evidence quality, interpretation, and important limits for insulin signaling, stem cell, and glucose metabolism studies.

• Protein A/G Magnetic Beads: Product Overview

  2026-10-09

  APExBIO’s Protein A/G Magnetic Beads (SKU K1305) are described as recombinant Protein A and Protein G beads for Fc-region IgG capture and related affinity workflows. No matched research paper was available, so performance, selectivity, and application-specific outcomes cannot be independently assessed.

• Exendin-4 in Type 2 Diabetes Research

  2026-10-09

  Exendin-4, also called Exenatide, is a GLP-1 receptor agonist studied in beta-cell biology, glucose regulation, and recombinant production. Current evidence supports a mechanistic research role and a yeast-expression proof of concept, but does not establish therapeutic equivalence, oral delivery, manufacturing feasibility, or clinical benefit from the 2024 study.

• Octanoic Acid, PPARγ, and Macrophage Balance in IBD

  2026-10-08

  A 2025 Food Science & Nutrition study links octanoic acid-rich enteral nutrition with improved inflammatory bowel disease phenotypes through coordinated PPARγ, STAT-1, and STAT-6 signaling. Its mouse and cell-based evidence supports a mechanistic model of macrophage-polarization control, while the absence of clinical data limits direct translation to patient care.

• Tiamulin (Thiamutilin): Evidence Overview

  2026-10-08

  Tiamulin, also called Thiamutilin in the supplied product dossier, is a pleuromutilin antibiotic used mainly in veterinary medicine. Evidence supports a 50S-ribosome mechanism, while anti-inflammatory and cross-species applications remain more context-dependent and require careful interpretation.

• Estradiol, ERα, and T Cells After Hemorrhagic Shock

  2026-10-07

  The 2021 Scientific Reports study links estradiol-mediated immune recovery after hemorrhagic shock to ERα- and GPR30-associated suppression of endoplasmic reticulum stress. Its pharmacological comparison of estrogen-receptor ligands and stress modulators provides a mechanistic framework, while the animal-model design limits direct translation to human trauma care or breast cancer biology.

• Drug-Sensitized Yeast for mTOR Inhibitor Discovery

  2026-10-07

  A 2025 GeroScience study introduces a genetically drug-sensitized yeast platform that substantially improves detection of TOR pathway inhibitors compared with a wild-type background. The system identified pathway-linked activity for established inhibitors and aminophylline, while finding no evidence of TOR inhibition for canagliflozin in this model, an important boundary for interpreting results in glucose metabolism research.

8720 records 1/582 page Next 12345 下5页 Last page